rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Precigen, Inc.

PGEN · Nasdaq

Health CareBiotechnologyLeading

PGEN stood above a rising 150-day average in 42 of the last 52 weekly readings, including each of the last 19 weeks. It is 16.9% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
19 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$49K
Insider sales, 12 months
$68.5M
Officials’ trades on record
0
Institutions holding
202 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 42 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$30.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months22
Buyers · sellers1 · 7
WhoDidSharesTraded
Jeffrey B. KindlerDirectorsold185,000at $7.4426 Aug 2026filed 28 Aug 2026
Phil TennantChief Commercial Officersold79,166at $7.5025 Aug 2026filed 25 Aug 2026
Rutul R. ShahChief Operating Officersold15,342at $7.5025 Aug 2026filed 25 Aug 2026
Rutul R. ShahChief Operating Officersold34,658at $7.5021 Aug 2026filed 25 Aug 2026
Nancy H. AgeeDirectorbought3,411at $7.2321 Aug 2026filed 25 Aug 2026
Rutul R. ShahChief Operating Officersold32,739at $6.866 Aug 2026filed 7 Aug 2026
Rutul R. ShahChief Operating Officersold33,772at $6.503 Aug 2026filed 3 Aug 2026
Harry Thomasian, Jr.Chief Financial Officersold100,000at $6.0631 Jul 2026filed 31 Jul 2026
Harry Thomasian, Jr.Chief Financial Officersold171,429at $5.531 Jul 2026filed 1 Jul 2026
Helen SabzevariPresident and CEOsold346,836at $5.8929 Jun 2026filed 1 Jul 2026
Rutul R. ShahChief Operating Officersold42,924at $5.8529 Jun 2026filed 1 Jul 2026
Harry Thomasian, Jr.Chief Financial Officersold28,571at $5.7829 Jun 2026filed 1 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders202+6 on the quarter
New · exited37 · 30
Reported value$802.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Patient Capital Management, LLCadded · filed 13 Aug 202619,036,976$108.5M+1,219,589+6.8%
BlackRock, Inc.added · filed 7 Aug 202617,146,921$97.7M+1,923,730+12.6%
STATE STREET CORPadded · filed 7 Aug 202612,002,465$68.4M+1,112,341+10.2%
Diametric Capital, LPadded · filed 14 Aug 20269,269,926$52.8M+2,468,138+36.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,906,160$45.1M+757,164+10.6%
TANG CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 20266,417,500$36.6M00.0%
Boxer Capital Management, LLCadded · filed 14 Aug 20265,150,000$29.4M+1,650,000+47.1%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20265,019,028$28.6M+405,599+8.8%
IRIDIAN ASSET MANAGEMENT LLCadded · filed 29 Jul 20264,031,963$23.0M+439,233+12.2%
Occam Crest Management LPreduced · filed 14 Aug 20263,605,941$19.7M-663,110−15.5%
31 Mar 2023 – 30 Jun 2026
108154199Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Harry Thomasian Jr. Company insiderChief Financial Officer · last 23 Sep 20265 · 9
Jeffrey B. Kindler Company insiderDirector · last 26 Aug 20262 · 6
Phil Tennant Company insiderChief Commercial Officer · last 25 Aug 20261 · 2
Rutul R. Shah Company insiderChief Operating Officer · last 25 Aug 20262 · 10
Donald P. Lehr Company insiderChief Legal Officer · last 23 Aug 20262 · 22
Helen Sabzevari Company insiderPresident and CEO · last 23 Aug 20261 · 25
Nancy H. Agee Company insiderDirector · last 21 Aug 20264 · 0
Randal J. Kirk Company insiderDirector, 10% owner · last 30 Mar 202659 · 8
Cesar L. Alvarez Company insiderDirector · last 13 Mar 20260 · 0
Fred Hassan Company insiderDirector · last 13 Mar 20262 · 0
James S. Turley Company insiderDirector · last 13 Mar 20260 · 0
Steven Frank Company insiderDirector · last 13 Mar 20261 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Free cash flow marginFY 2025 · to 31 Dec 2025-928%
Return on capital employedFY 2025 · to 31 Dec 2025-93.5%
Debt to equityFY 2025 · to 31 Dec 20254.46×
Research spendFY 2025 · to 31 Dec 2025427%
Share count trendFY 2025 · to 15 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$30.2M
Free cash flowFY 2025 · to 31 Dec 2025−$89.8M

Analyst forecasts

No analyst forecasts yet.